CHENGDU, China I January 07, 2025 I The board (the “Board”) of directors (“Directors”) of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”) is ...
CHENGDU, China I January 20, 2025 I Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”) has received marketing authorization in China from ...
SHANGHAI, China I January 20, 2025 I YolTech Therapeutics, a clinical-stage gene editing company dedicated to delivering lifelong cures, announced the ...
Junshi Biosciences Announces Commercialization Partnership with LEO Pharma for Toripalimab in Europe
SHANGHAI, China I, 2025 I Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...
SHANGHAI, China I, 2025 I CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the ...
BEIJING, China I, 2025 I InnoCare Pharma (HKEX: 09969; SSE: 688428) and KeyMed Biosciences (HKEX: 02162) today announced that the two companies, ...
PLANEGG-MARTINSRIED, Germany I January 20, 2025 I Formycon AG (FSE: FYB, Prime Standard, “Formycon”) and its licensing partner Klinge Biopharma GmbH (“Klinge”) today jointly announce that the European ...
TOKYO, Japan & BASKING RIDGE, NJ, USA I January 17, 2055 I DATROWAY ® (datopotamab deruxtecan-dlnk) has been approved in the U.S. for the treatment of adult patients with unresectable or metastatic ...
Based on ECHO Phase III trial results which showed more than 16 months of progression-free survival improvement vs. chemoimmunotherapy alone First and only BTK inhibitor approved for the 1st-line ...
“Colorectal cancer is the third leading cause of cancer-related deaths in the United States, and fewer than one in five people diagnosed with metastatic disease survive beyond five years after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback